Cytokinetics
Cytokinetics, Incorporated is a late-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing muscle biology therapeutics for debilitating diseases. The company develops small-molecule drug candidates targeting cardiac and skeletal muscle function, with lead compounds aimed at treating heart failure, hypertrophic cardiomyopathy, and amyotrophic lateral sclerosis. Revenue is primarily generated through strategic licensing agreements, research and development milestones, and royalty revenues from pharmaceutical development partners. Cytokinetics serves clinical research centers, cardiology specialists, neurology practices, and healthcare providers globally. The enterprise holds an established pioneer position in the scientific discovery of novel muscle activators and inhibitors within the global biopharmaceutical industry. Cytokinetics, Incorporated is headquartered in South San Francisco, California, United States, and its common stock is listed on the Nasdaq Global Select Market.
15 of the funds FundTelligence covers report a position in Cytokinetics.
- Legal name
- Cytokinetics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 15
Funds holding Cytokinetics
- DNB Bioteknologi — DNB · 1.77 % (full portfolio disclosed, September 2026)
- BNP Health Care Innovators — BNP Paribas · 1.26 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 1.18 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.09 % (full portfolio disclosed, September 2026)
- BNP US Growth — BNP Paribas · 1.03 % (full portfolio disclosed, June 2026)
- Lannebo Global — Lannebo · 0.82 % (full portfolio disclosed, June 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.79 % (full portfolio disclosed, October 2026)
- JPM US Small Cap Growth Fund — JPM · 0.72 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 15 funds holding it.